HK Neopharm Limited is one of the most reliable manufacturers and suppliers of bonista of injection in China, featured by quality products and good price. Please rest assured to buy bonista of injection in stock here and get quotation from our factory. Customized orders are welcome.
Teriparatide Injection is a world-leading recombinant human parathyroid hormone (PTH 1-34) analog and one of the few clinically available bone-forming agents (anabolic agents) for the treatment of osteoporosis at high risk of fracture. Through once-daily precise pulsed administration, it preferentially stimulates osteoblast activity, promotes new bone formation, significantly increases bone mineral density, and improves bone microarchitecture, thereby reducing vertebral and non-vertebral fracture risk.
The active ingredient, Teriparatide, is a recombinant peptide consisting of the N-terminal 34 amino acid sequence of endogenous parathyroid hormone, with biological properties identical to endogenous PTH. By targeting and binding to the parathyroid hormone type 1 receptor (PTH1R) on the surface of bone cells, it activates the bone anabolic signaling pathway, achieving a balanced regulation of bone formation and bone resorption.
Technical Specifications
|
Product Name |
Teriparatide Injection |
|
Synonyms |
teriparatide injection dose |
|
Characteristics |
White to off-white Solid |
|
CAS Number |
52232-67-4 |
|
Assay |
≥99.0% (HPLC, Subject to the COA) |
|
Formula |
C181H291N55O51S2 |
|
Package |
Technical Package |
|
Storage |
Store at 2～8℃ |
|
Structure |
|
As the first bone-forming agent approved for marketing, this product has been launched in the United States (first approved in 1997), Europe, Japan, China, and many other countries and regions. It provides breakthrough treatment options for postmenopausal women with osteoporosis, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis. According to IQVIA data, the total U.S. market sales of teriparatide injection in 2025 reached approximately USD 585 million.
Product Features
Unique mechanism of action targeting bone metabolism pathway
Teriparatide Injection, administered via once-daily intermittent subcutaneous injection, mimics the physiological pulsed secretion pattern of PTH. It preferentially activates the Wnt/β-catenin signaling pathway in osteoblasts, promotes new bone formation, improves trabecular thickness and connectivity, repairs bone microstructural defects, and increases bone mass and strength.
Strict quality standard system
The product is produced using recombinant DNA technology with full-process traceability control from starting materials to finished product testing. Each batch undergoes multi-dimensional quality control including HPLC purity analysis, content assay, related substances testing, residual solvent inspection, microbial limits, and endotoxin testing. The quality system complies with ICH Q7 and major pharmacopoeia standards. As a leading China Teriparatide Injection supplier, we ensure every batch meets global regulatory requirements. Our Customized Teriparatide Injection service allows adjustment of packaging, labeling, and technical documentation to suit specific client needs.
Stable physicochemical properties and formulation design
Teriparatide Injection is a colorless, clear sterile solution with a pH range of 3.8–4.5. The fixed daily dose of 20 μg simplifies administration. The drug concentration is 250 μg/mL, and the single injection volume is only 80 μL, providing a good injection experience. The prefilled pen design allows for easy self-administration by patients after training.
Full-Cycle Quality Control & Consistent Quality
Teriparatide Injection is produced using recombinant DNA technology with highly purified process control to ensure high purity, uniformity, and biological activity. Each batch undergoes rigorous quality testing covering peptide sequence confirmation, purity (HPLC), sterility, endotoxin, bioactivity, and other full-dimension indicators, meeting ICH Q7 and multiple pharmacopoeia standards.
As a core product in the global osteoporosis treatment field, the quality system of Teriparatide Injection is benchmarked against the highest international standards. The product is widely recognized in major markets such as the US, Europe, and Japan, providing compliant quality assurance for finished formulations entering the global market. The manufacturing enterprises hold cGMP, FDA, and other multinational certifications, supporting global registration filings. When you evaluate teriparatide generic cost, our transparent pricing model offers excellent value. We also provide Teriparatide Injection made in China with proven track record of exports to over 60 countries.
Application Scenarios
1. Treatment of Postmenopausal Osteoporosis
For postmenopausal women with high fracture risk (prior osteoporotic fracture history or multiple risk factors) or those who have failed or are intolerant to other osteoporosis treatments. This product significantly increases lumbar spine and femoral neck bone mineral density, reduces vertebral and non-vertebral fracture risk, and is a first-line bone-forming therapy recommended by clinical guidelines.
2. Treatment of Male Osteoporosis
For men with primary or hypogonadal osteoporosis at high fracture risk. Daily 20 μg subcutaneous injection of this product significantly increases bone mass and improves bone quality, making it an important treatment option for male osteoporosis.
3. Glucocorticoid-Induced Osteoporosis (GIOP)
Patients on long-term glucocorticoid therapy (daily prednisone ≥5 mg) have a significantly increased risk of osteoporosis. Teriparatide is an FDA-approved bone-forming agent for GIOP, actively building new bone to effectively counteract hormone-induced bone loss.
4. Postoperative Healing of Osteoporotic Fractures
Clinical studies have confirmed that 12 weeks of Teriparatide treatment after hip fracture surgery significantly shortens fracture healing time, providing an innovative solution for accelerated rehabilitation in postoperative fracture patients.
5. Innovative Drug R&D and Reference Standard
Teriparatide API can be used as a reference standard and control substance to support the R&D of novel bone-forming agents, PTH analogs, oral peptide delivery systems, and other innovative formulations, helping to drive technological breakthroughs in the osteoporosis treatment field. For clients who need to understand teriparatide injection how to use, we provide detailed instructions and technical support. As a reputable terifrac injection company, we stand behind every shipment with complete documentation.
Packaging and Transportation
Teriparatide Injection is packaged in a prefilled pen injector, each containing 560 μg/2.24 mL (250 μg/mL), providing 28 daily doses. The product is shipped under full cold chain conditions (2℃-8℃) with real-time temperature monitoring equipment.
Transportation complies with international cold chain standards and the import regulatory requirements of various countries. Complete customs clearance documentation is available, supporting global distribution.
Standard packaging: Single prefilled pen (28 doses/pen) per box.
MOQ: Single pen for commercial packaging; bulk orders supported with volume discounts.
Our Advantages
Unique mechanism of action – builds new bone
Unlike traditional anti-resorptive drugs, this once-daily intermittent administration preferentially stimulates osteoblast activity, actively promotes new bone formation on cancellous and cortical bone surfaces, achieving continuous improvement in bone mineral density and significant reduction in fracture risk.
01
Broad indication coverage
Covers three major indications: postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis, meeting the treatment needs of various high fracture risk patients.
02
Convenient patient administration experience
Once-daily subcutaneous injection with a prefilled pen design allows patients to self-administer after training, greatly improving long-term treatment compliance.
03
Mature and stable supply chain guarantee
The product originates from modern production facilities compliant with cGMP/FDA standards, with a mature quality system and stable production capacity, supporting the full cycle from R&D trials to commercial mass production.
04
Flexible cooperation models
We offer multiple packaging specifications (20 μg single unit/bulk), customized labeling and packaging services, and support technology data sharing and registration document assistance, helping formulation companies quickly enter global markets. Whether you need Bulk Teriparatide Injection for large-scale production or a small batch for R&D, we can accommodate your requirements. Ask about our Teriparatide Injection Free Sample program to evaluate quality firsthand. For up-to-date Teriparatide Injection price, please contact our sales team.
05
FAQ
For any inquiries regarding Teriparatide Injection price, teriparatide generic cost, buy Teriparatide Injection, or to request a Teriparatide Injection Free Sample, please contact our team. We are a trusted China Teriparatide Injection manufacturer, supplier, and factory offering Customized Teriparatide Injection and Bulk Teriparatide Injection with Teriparatide Injection in stock. We also welcome partners interested in teriparatide injection dose guidance and teriparatide injection how to use training materials. As a professional terifrac injection company, we are committed to your success.
Hot Tags: bonista of injection, China bonista of injection manufacturers, suppliers, factory
